Covid vaccine to be available by 'start of next year': Harsh Vardhan

Harsh Vardhan in Rajya Sabha said that the coronavirus vaccine will be made available in the country by the start of next year. The remarks come at a time when India is recording more than 50 lakh cases and people are awaiting the vaccine with bated breath.

New Delhi:Union Health Minister Harsh Vardhan on Thursday said that the coronavirus vaccine will be made available in the country by the start of next year. The remarks come at a time when India is recording more than 50 lakh cases and people are awaiting the vaccine with bated breath.

"Just like other countries, India is also making efforts. Three vaccines candidates are in different phases. Under Prime Minister's guidance, an expert group is looking at it and there is advanced planning in place. We are hopeful that by the start of next year a vaccine will be available in India," Harsh Vardhan said in Rajya Sabha.

Two indigenous vaccines by Zydus Cadila and Bharat Biotech have completed phase 1. Serum Institute of India (SII) has again commenced the trials after getting clearance from the Drug Controller General of India.

India is the manufacturing partner of the vaccine candidate named Covishield, developed jointly by the University of Oxford's Jenner Institute's and AstraZeneca. The Pune-based firm, SII, is looking after the trials at 17 trial sites across India.

Besides this, the Russian Direct Investment Fund (RDIF) and Dr. Reddy's Laboratories Limited, a global pharmaceutical company headquartered out of India, have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India.

Sputnik V, an adenovirus vector-based vaccine, was developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, along with the Russian Direct Investment Fund and registered on August 11.

"On regulatory approval in India, RDIF shall supply to Dr. Reddy's 100 million doses of the vaccine. The Sputnik V vaccine, which is based on well-studied human adenoviral vector platform with proven safety, is undergoing clinical trials for the coronavirus pandemic," said a statement from the fund.